Does Rallies show 13F holders for ENGN?

Yes. Rallies tracks hedge fund and 13F ownership data for ENGN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ENGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ENGN. It does not provide personalized investment advice.

ENGN (enGene Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

enGene Therapeutics Inc. Common Stock (ENGN) is a publicly traded Healthcare sector company. As of May 21, 2026, ENGN trades at $1.55 with a market cap of $105.17M and a P/E ratio of 0.70. ENGN moved +5.88% today. Year to date, ENGN is -81.56%; over the trailing twelve months it is -61.67%. Its 52-week range spans $1.40 to $12.25. Analyst consensus is buy with an average price target of $8.69. Rallies surfaces ENGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ENGN stock?

Hedge funds tracked by Rallies that own ENGN include Orbimed Advisors. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for enGene Therapeutics Inc. Common Stock.

ENGN Key Metrics

Key financial metrics for ENGN
Metric	Value
Price	$1.55
Market Cap	$105.17M
P/E Ratio	0.70
EPS	$2.29
Dividend Yield	0.13%
52-Week High	$12.25
52-Week Low	$1.40
Volume	1.16K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-117.30M
Gross Margin	0.00%

Top Hedge Funds Holding ENGN

Orbimed Advisors holds 677.98K shares of ENGN, changed -23.96% as of Jun 30, 2025.

Latest ENGN News

Analysts Slash enGene Price Targets 40% After ENG-1 Trial Misses Endpoints — May 8, 2026
enGene Hits 62% CR in 125-Patient LEGEND Trial, Plans BLA by End-2026 — Feb 28, 2026

Recent ENGN Insider Trades

Forbion Growth Opportunities Fund I Cooperatief U.A. bought 561.80K (~$5.00M) on Oct 30, 2024.
Forbion Growth Opportunities Fund I Cooperatief U.A. bought 800 (~$5.28K) on Oct 8, 2024.
Forbion Growth Opportunities Fund I Cooperatief U.A. bought 11.84K (~$77.53K) on Oct 7, 2024.

ENGN Analyst Consensus

12 analysts cover ENGN: 0 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.69.

Common questions about ENGN

Who owns ENGN stock?: Hedge funds tracked by Rallies that own ENGN include Orbimed Advisors. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for enGene Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for ENGN?: Yes. Rallies tracks hedge fund and 13F ownership data for ENGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ENGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ENGN. It does not provide personalized investment advice.